Sytheon Patents Isosorbide Esters for Skin Diseases, Enters Dermatological Market

Sytheon inventors have discovered certain esters of isosorbide can modify and regulate the expression of genes, genetic networks, and cellular pathways in the skin. The company has patented this invention for the dermatology market.

Assigned to Sytheon, U.​S. Patent 10,597,402 discloses, “compositions and methods for restoring epidermal integrity and function and treating dermatol­ogical diseases.” According to the company, these esters can be used to improve and/​or address defects or imbalances in keratinocyte differen­tiation.

They also can repair skin barrier building and defend its functioning and integrity, improving overall stratum corneum development, structure, and architecture. Furthermore, the esters are reportedly effective for combating, mitigating, and/or preventing the manifestation of diseased conditions, defects, or imbalances in the skin.

Securing this patent, Sytheon stakes claim through its sister company, Symbionyx Phamaceu­ticals Inc., in the dermatol­ogical market to treat diseases caused by autoimmune imbalances.

For more information, please contact: info@symbionyx.com or sohini@sytheonltd.com

Sytheon/Symbionyx Expand the Scope of Isosorbide Esters

Sytheon/Symbionyx Expand the Scope of Isosorbide Esters

Transforming a Skin Sensitizer to a NON-Skin Sensitizer Sytheon/Symbionyx researchers published a paper – “A sensitization-free dimethyl fumarate (DMF) pro-drug, isosorbide di-(methyl fumarate) (IDMF), provides a topical treatment candidate for psoriasis” in JID...

Sytheon/Symbionyx Raise the Limit of Isosorbide Esters to the Max

Sytheon/Symbionyx Raise the Limit of Isosorbide Esters to the Max

From Skin Care to Brain Care Sytheon/Symbionyx researchers published a paper – “A novel fumarate, isosorbide di-(methyl fumarate) (IDMF), replicates astrocytes transcriptome responses to dimethyl fumarate (DMF) but specifically down-regulates genes linked to a...